Creating the next generation of protein therapeutics through rational drug design

Current Opinion in Drug Discovery and Development

Volumn 8, Issue 5, 2005, Pages 590-600

  Szymkowski, David E ^a  

^a Xencor Inc   (United States)

Author keywords

Biopharmaceuticals; Biotherapeutics; High throughput screening; Medicinal biology; Monoclonal antibodies; Protein design; Protein engineering

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEFACEPT; ALEMTUZUMAB; ALPHA 1 ANTITRYPSIN; ASPARAGINASE MACROGOL; BASILIXIMAB; BEVACIZUMAB; CETUXIMAB; CONSENSUS INTERFERON; DACLIZUMAB; ETANERCEPT; IBRITUMOMAB TIUXETAN; IMIGLUCERASE; IMMUNOGLOBULIN ANTIBODY; INFLIXIMAB; INSULIN ASPART; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INTERFERON BETA SERINE; MONOCLONAL ANTIBODY; NATALIZUMAB; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OMALIZUMAB; PALIVIZUMAB; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGVISOMANT; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; RECOMBINANT PROTEIN; RETEPLASE; TENECTEPLASE; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; XMAB;

DRUG DESIGN; DRUG RELEASE; DRUG STABILITY; PROTEIN ENGINEERING; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; SUSTAINED RELEASE PREPARATION;

ANIMALS; DRUG DESIGN; HUMANS; PROTEIN ENGINEERING; RECOMBINANT PROTEINS;

EID: 24044442890     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Walsh G: Biopharmaceutical benchmarks - 2003. Nat Biotechnol (2003) 21(8):865-870.
2. Relchert JM: Trends in development and approval times for new therapeutics in the United States. Nat Rev Drug Discov (2003) 2(9):695-702.
3. Pavlou AK, Reichert JM: Recombinant protein therapeutics - success rates, market trends and values to 2010. Nat Biotechnol (2004) 22(12):1513-1519. Provides a comprehensive overview of the global market for protein drugs, including overall sales by therapy area, by product and by company, with recent historical data plus a six-year forecast.
4. Bonin-Debs AL, Boche I, Gille H, Brinkmann U: Development of secreted proteins as biotherapeutic agents. Expert Opin Biol Ther (2004) 4(4):551-558.
5. Zambrowicz BP, Sands AT: Knockouts model the 100 best-selling drugs - will they model the next 100? Nat Rev Drug Discov (2003) 2(1):38-51.
6. White CA, Larocca A, Grillo-Lopez AJ: Anti-CD20 monoclonal antibodies as novel treatments for non-Hodgkin's lymphoma. Pharm Sci Technol Today (1999) 2(3):95-101.
7. Grillo-Lopez AJ: Zevalin: The first radioimmunotherapy approved for the treatment of lymphoma. Expert Rev Anticancer Therapy (2002) 2(5):485-493.
8. Friedberg JW, Fisher RI: Iodine-131 tositumomab (Bexxar): Radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma. Expert Rev Anticancer Therapy (2004) 4(1):18-26.
9. Marshall SA, Lazar GA, Chirino AJ, Desjarlais JR: Rational design and engineering of therapeutic proteins. Drug Disc Today (2003) 8(5):212-221.
10. Vasserot AP, Dickinson CD, Tang Y, Huse WD, Manchester KS, Watkins JD: Optimization of protein therapeutics by directed evolution. Drug Disc Today (2003) 8(3):118-126. Provides a good overview of codon-based and other mutagenesis techniques to generate protein library diversity ('directed evolution').
11. Leong SR, Chang JC, Ong R, Dawes G, Stemmer WP, Punnonen J: Optimized expression and specific activity of IL-12 by directed molecular evolution. Proc Natl Acad Sci USA (2003) 100(3):1163-1168.
12. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK: Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum (2003) 48(1):35-45.
13. Hayes RJ, Bentzien J, Ary ML, Hwang MY, Jacinto JM, Vielmetter J, Kundu A, Dahiyat BI: Combining computational and experimental screening for rapid optimization of protein properties. Proc Natl Acad Sci USA (2002) 99(25):15926-15931. Description of a general protein optimization strategy incorporating structure-based computational screening and high-throughput expression and activity assays of a large protein library.
14. Baigent G: Recombinant interleukin-2 (rlL-2), aldesleukin. J Biotechnol (2002) 95(3):277-280.
15. Horowski R: Multiple sclerosis and Interferon β-1b, past, present and future. Clin Neurol Neurosurg (2002) 104(3):259-264.
16. Sarkar CA, Lowenhaupt K, Horan T, Boone TC, Tidor B, Lauffenburger DA: Rational cytokine design for increased lifetime and enhanced potency using pH-activated "histidine switching" Nat Biotechnol (2002) 20(9):908-913. Discusses the use of surface engineering to improve half-life by inducing efficient endosomal recycling. Suggests a broadly applicable new approach to improve the pharmacokinetics of protein drugs.
17. Hinton PR, Johlfs MG, Xiong JM, Hanestad K, Ong KC, Bullock C, Keller S, Tang MT, Tso JY, Vasquez M, Tsurushita N: Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem (2004) 279(8):6213-6216.
18. Filikov AV, Hayes RJ, Luo P, Stark DM, Chan C, Kundu A, Dahiyat BI: Computational stabilization of human growth hormone. Protein Sci (2002) 11(6):1452-1461.
19. Luo P, Hayes RJ, Chan C, Stark DM, Hwang MY, Jacinto JM, Juvvadi P, Chung HS, Kundu A, Ary ML, Dahiyat BI: Development of a cytokine analog with enhanced stability using computational ultrahigh throughput screening. Protein Sci (2002) 11(5):1218-1226.
20. Chance RE, Frank BH, Radziuk JM, DiMarchi RD: Discovery and development of insulin lispro. Drugs Today (1998) 34(Suppl C):1-9.
21. Reynolds NA, Wagstaff AJ: Insulin aspart: A review of its use in the management of type 1 or 2 diabetes mellitus. Drugs (2004) 64(17):1957-1974.
22. Gerich JE: Insulin glargine: Long-acting basal insulin analog for improved metabolic control. Curr Med Res Opin (2004) 20(1):31-37.
23. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood (2002) 99(3):754-758.
24. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, Fox JA et al: High resolution mapping of the binding site on human IgGI for FcγRI, FcγRII, FcγRIII and FcRn and design of IgG1 variants with improved binding to the FcγR. J Biol Chem (2001) 276(9):6591-6604. Demonstrates that antibody affinity for Fc receptors can be improved by amino acid engineering, translating into improved tumor cell-killing by Fc variants of Herceptin® therapeutic antibody.
25. Griffiths AD, Duncan AR: Strategies for selection of antibodies by phage display. Curr Opin Biotechnol (1998) 9(1):102-108.
26. Kellermann SA, Green LL: Antibody discovery: The use of transgenic mice to generate human monoclonal antibodies for therapeutics. Curr Opin Biotechnol (2002) 13(6):593-597.
27. Murray KM, Dahl SL: Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis. Ann Pharmacother (1997) 31(11):1335-1338.
28. Dall'Era M, Davis J: CTLA4Ig: A novel inhibitor of costimulation. Lupus (2004) 13(5):372-376.
29. Zocher M, Baeuerle PA: A bispecific single-chain antibody fusion protein for targeted depletion of autoreactive B cells via unstimulated human T lymphocytes. Mol Immunol (2004) 41(5):511-518. Discusses the design of a bispecific fusion, which specifically targets MOG-autoreactive B-cells by recruiting non-specific cytotoxic T-cells via the anti-CD3 antibody domain.
30. Bitonti AJ, Dumont JA, Low SC, Peters RT, Kropp KE, Palombella VJ, Stattel JM, Lu Y, Tan CA, Song JJ, Garcia AM et al: Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci USA (2004) 101(26):9763-9768. Discusses the pulmonary delivery of erythropoietin enabled by conjugation to IgG1 to induce FcRn receptor-mediated transport across airway epithelium. Opens new possibilities for systemic delivery of large proteins through a non-invasive route.
31. Santoro SW, Wang L, Herberich B, King DS, Schultz PG: An efficient system for the evolution of aminoacyl-tRNA synthetase specificity. Nat Biotechnol (2002) 20(10):1044-1048.
32. Zhang Z, Alfonta L, Tian F, Bursulaya B, Uryu S, King DS, Schultz PG: Selective incorporation of 5-hydroxytryptophan into proteins in mammalian cells. Proc Natl Acad Sci USA (2004) 101(24):8882-8887. Provides the first example of engineering a mammalian cell line (293T) to allow selective incorporation of an unnatural amino acid at a defined site.
33. Gemgross TU: Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nat Biotechnol (2004) 22(11):1409-1414.
34. Sodoyer R: Expression systems for the production of recombinant pharmaceuticals. BioDrugs (2004) 18(1):51-62.
35. Gomord V, Faye L: Posttranslational modification of therapeutic proteins in plants. Curr Opin Plant Biol (2004) 7(2):171-181.
36. Elliott S, Lorenzini T, Asher S, Aoki K, Brankow D, Buck L, Busse L, Chang D, Fuller J, Grant J, Hernday N et al: Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol (2003) 21(4):414-421. Introduction of additional N-linked carbohydrate chains into several unrelated proteins, showing that glycoengineering is a broadly applicable protein drug design tool.
37. Elliott S, Chang D, Delorme E, Eris T, Lorenzini T: Structural requirements for additional N-linked carbohydrate on recombinant human erythropoietin. J Biol Chem (2004) 279(16):16854-16862.
38. Umaña P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE: Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol (1999) 17(2):176-180.
39. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, Hanai N et al: The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem (2003) 278(5):3466-3473. Describes a glycoform engineering approach to improving tumor-killing effector function of antibodies.
40. Chirino AJ, Mire-Sluis A: Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol (2004) 22(11):1383-1391. Provides a good overview of strategies to predict, detect and reduce the immunogenicity of protein drugs prior to clinical development.
41. Dahiyat B: Antibody Fc engineering. 4th International Congress on Monoclonal Antibodies in Cancer, Colorado Springs, CO, USA (2004).
42. Morpurgo M, Veronese FM: Conjugates of peptides and proteins to polyethylene glycols. Methods Mol Biol (2004) 283:45-70.
43. Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE, Ehrlich GK, Pan W, Xu ZX, Modi MW, Farid A et al: Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C. Bioconjug Chem (2001) 12(2):195-202. Provides an example of how pegylation improves pharmacokinetics while reducing drug potency, and also describes the pegylation of IFNα-2a (Roferon®-A) to create a new drug (Pegasys®) with an improved serum half-life, yet with substantial loss of in vitro antiviral activity.
44. Steed PM, Tansey MG, Zalevsky J, Zhukovsky EA, Desjarlais JR, Szymkowski DE, Abbott C, Carmichael D, Chan C, Cherry L, Cheung P et al: Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science (2003) 301(5641):1895-1898. Exemplifies a new mechanism to antagonize TNF signaling via subunit exchange of inactive TNF variant with bioactive native cytokine, combined with structure-guided site-directed pegylation to maintain compound activity.
45. Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, Kuter DJ: Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood (2001) 98(12):3241-3248.
46. Sievers EL: Antibody-targeted chemotherapy of acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg). Blood Cells Mol Dis (2003) 31(1):7-10.
47. Murphy JR, vanderSpek JC: Targeting diphtheria toxin to growth factor receptors. Semin Cancer Biol (1995) 6(5):259-267.
48. Goffin V, Bernichtein S, Carriere O, Bennett WF, Kopchick JJ, Kelly PA: The human growth hormone antagonist B2036 does not interact with the prolactin receptor. Endocrinology (1999) 140(8):3853-3856. Provides an example of a marketed drug (Somavert®) engineered to introduce two novel functions: transformation of HGH into a GHR antagonist, and elimination of drug binding to PRLR to avoid potential side effects.
49. Gao Y, Brimijoin S: An engineered cocaine hydrolase blunts and reverses cardiovascular responses to cocaine in rats. J Pharmacol Exp Ther (2004) 310(3):1046-1052. Discusses the engineering of human plasma BChE with two amino acid changes for greater cocaine hydrolysis activity. The engineered enzyme provided increased cocaine clearance in rats.
50. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C, Bianchi M, Nielsen J, Gerwien J, Kallunki P et al: Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science (2004) 305(5681):239-242. Demonstrates the ability to engineer novel properties into a cytokine (elimination of binding to the classical erythropoietin receptor while maintaining a desired secondary activity), even when the receptor involved in the desired function is unknown.
51. Kochendoerfer GG, Chen SY, Mao F, Cressman S, Traviglia S, Shao H, Hunter CL, Low DW, Cagle EN, Carnevali M, Gueriguian V et al: Design and chemical synthesis of a homogeneous polymer-modified erythropoiesis protein. Science (2003) 299(5608):884-887. Presents the total chemical synthesis of an engineered erythropoietin-like protein of 166 amino acids conjugated to a defined polymer. The modified protein demonstrated in vivo erythropoietic activity.
52. Barnett AH: Exubera inhaled insulin: A review. Int J Clin Pract (2004) 58(4):394-401.
53. Chirino AJ, Ary ML, Marshall SA: Minimizing the immunogenicity of protein therapeutics. Drug Disc Today (2004) 9(2):82-90.
54. Tangri S, LiCalsi C, Sidney J, Sette A: Rationally engineered proteins or antibodies with absent or reduced immunogenicity. Curr Med Chem (2002) 9(24):2191-2199.
55. Im H, Ryu MJ, Yu MH: Engineering thermostability in serine protease inhibitors. Protein Eng Des Sel (2004) 17(4):325-331.
56. Barlocco D: Insulin glulisine. Aventis Pharma. Curr Opin Invest Drugs (2003) 4(10):1240-1244.
57. Blatt LM, Davis JM, Klein SB, Taylor MW: The biologic activity and molecular characterization of a novel synthetic interferon-α species, consensus interferon. J Interferon Cytokine Res (1996) 16(7):489-499.
58. Davydov L, Cheng JW: Tenecteplase: A review. Clin Ther (2001) 23(7):982-997.
59. Bashir SJ, Maibach HI: Alefacept (Biogen). Curr Opin Invest Drugs (2001) 2(5):631-634.
60. Smalling RW: Molecular biology of plasminogen activators: What are the clinical implications of drug design? Am J Cardiol (1996) 78(12A):2-7.
61. Sandberg H, Almstedt A, Brandt J, Castro VM, Gray E, Holmquist L, Lewin M, Oswaldsson U, Mikaelsson M, Jankowski MA, Bond M et al: Structural and functional characterization of B-domain deleted recombinant Factor VIII. Semin Hematol (2001) 38(2 Suppl 4):4-12.
62. Overholser JP, Prewett MC, Hooper AT, Waksal HW, Hicklin DJ: Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer (2000) 89(1):74-82.
63. Mouser JF, Hyams JS: Infliximab: A novel chimeric monoclonal antibody for the treatment of Crohn's disease. Clin Ther (1999) 21(6):932-942.
64. Hayes R, Chesebro JH, Fuster V, Dangas G, Fallon JT, Sharma SK, Coller BS, Badimon L, Marmur JD, Badimon JJ: Antithrombotic effects of abciximab. Am J Cardiol (2000) 85(10):1167-1172.
65. Onrust SV, Wiseman LR: Basiliximab. Drugs (1999) 57(2):207-213.
66. Lin KC, Castro AC: Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents. Curr Opin Chem Biol (1998) 2(4):453-457.
67. Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P, de Vos AM, Lowman HB: Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol (1999) 293(4):865-881.
68. Waldmann H, Polliak A, Hale G, Or R, Cividalli G, Weiss L, Weshler Z, Samuel S, Manor D, Brautbar C et al: Elimination of graft-versus-host disease by In vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet (1984) 2(8401):483-486.
69. Goldenberg MM: Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther (1999) 21(2):309-318.
70. Scott LJ, Lamb HM: Palivizumab. Drugs (1999) 58(2):305-311.
71. Easthope S, Jarvis B: Omalizumab. Drugs (2001) 61(2):253-260.
72. Waldmann TA, O'Shea J: The use of antibodies against the IL-2 receptor in transplantation. Curr Opin Immunol (1998) 10(5):507-512.
73. Zimran A, Elstein D, Levy-Lahad E, Zevin S, Hadas-Halpem I, Bar-Ziv Y, Foldes J, Schwartz AJ, Abrahamov A: Replacement therapy with imiglucerase for type 1 Gaucher's disease. Lancet (1995) 345(8963):1479-1480.
74. Pedder SC: Pegylation of Interferon alfa: Structural and pharmacokinetic properties. Semin Liver Dis (2003) 23(Suppl 1):19-22.
75. Molineux G: The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des (2004) 10(11):1235-1244.
76. Graham ML: Pegaspargase: A review of clinical studies. Adv Drug Deliv Rev (2003) 55(10):1293-1302.
77. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL et al: cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood (2003) 102(4):1458-1465.